ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Lambe T., Spencer A., Thomas K., Thomas S., White A., Humphries H., Wright D., Thakur N., Conceicao C., Alden L., Allen L., Aram M., Bewley K., Brunt E., Brown P., Cavell B., Cobb R., Fotheringham S., Gilbride C., Harris D., Ho C., Hunter L., Kennard C., Leung S., Lucas V., Ngabo D., Ryan K., Sharpe H., Sarfas C., Sibley L., Slack G., Ulaszewska M., wand N., Wiblin N., Gleeson F., Bailey D., Sharpe S., Charlton S., Salguero F., Carroll M., Gilbert S.
<jats:title>Abstract</jats:title> <jats:p>Vaccines against SARS-CoV-2 are urgently required. Here we report detailed immune profiling after ChAdOx1 nCoV-19 (AZD1222) and subsequent challenge in two animal models of SARS-CoV-2 mediated disease. We demonstrate in rhesus macaques the lung pathology caused by SARS-CoV-2 mediated pneumonia is reduced by prior vaccination with ChAdOx1 nCoV-19 which induced neutralising antibody responses after a single intramuscular administration. In a second animal model, ferrets, ChAdOx1 nCoV-19 reduced both virus shedding and lung pathology. Antibody titers were boosted by a second dose. Data from these challenge models and the detailed immune profiling, support the continued clinical evaluation of ChAdOx1 nCoV-19.</jats:p>